A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas

Neurosurgery

Volumn 73, Issue 1, 2013, Pages 8-17

  Jahangiri, Arman ^a   Wagner, Jeffrey R ^b   Pekmezci, Melike ^c   Hiniker, Anne ^c   Chang, Edward F ^b   Kunwar, Sandeep ^a   Blevins, Lewis ^a,c   Aghi, Manish K ^a  

^a California Center for Pituitary Disorders at UCSF   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenocorticotropic hormone; Cushing disease; Nonfunctioning; Pituitary tumors; Recurrence; Silent corticotrophic

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE;

ADENOMA; ADULT; ARTICLE; CAVERNOUS SINUS; COMPARATIVE STUDY; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; FEMALE; HORMONE NEGATIVE ADENOMA; HUMAN; HYDROCORTISONE BLOOD LEVEL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILENT CORTICOTROPHIC ADENOMA;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; FEMALE; HUMANS; HYDROCORTISONE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; SAN FRANCISCO; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880572492     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.neu.0000429858.96652.1e     Document Type: Article

References (21)

1. Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C. Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. A distinct clinicopathologic entity. Am J Med. 1978;64(3):492-499
2. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W. Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol. 1980;98(3):617-638
3. Scheithauer BW, Jaap AJ, Horvath E, et al. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery. 2000;47(3):723-729; discussion 729-730
4. Yamada S, Ohyama K, Taguchi M, et al. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery. 2007;61(3):580-584; discussion 584-585
5. Baldeweg SE, Pollock JR, Powell M, Ahlquist J. A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg. 2005;19(1):38-42
6. Horvath E, Kovacs K, Smyth HS, et al. A novel type of pituitary adenoma: morphological features and clinical correlations. J Clin Endocrinol Metab. 1988;66 (6):1111-1118
7. Lopez JA, Kleinschmidt-Demasters Bk B, Sze CI, Woodmansee WW, Lillehei KO. Silent corticotroph adenomas: further clinical and pathological observations. Hum Pathol. 2004;35(9):1137-1147
8. Ohta S, Nishizawa S, Oki Y, Yokoyama T, Namba H. Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I-immunohistochemical study. Pituitary. 2002;5(4):221-223
9. Ioachimescu AG, Eiland L, Chhabra VS, et al. Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative Non-functioning pituitary adenomas. Neurosurgery. 2012;71(2):296-303
10. Alahmadi H, Lee D, Wilson JR, et al. Clinical features of silent corticotroph adenomas. Acta Neurochir (Wien). 2012;154(8):1493-1498
11. Raverot G, Wierinckx A, Jouanneau E, et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol. 2010;163(1):35-43
12. Cho HY, Cho SW, Kim SW, Shin CS, Park KS, Kim SY. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf). 2010;72(5):648-653
13. Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER Jr. Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery. 2003;53(5):1076-1084; discussion 1084-1085
14. Bradley KJ, Wass JA, Turner HE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf). 2003;58(1):59-64
15. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J. 2009;56(4):579-584
16. Rousseau K, Kauser S, Pritchard LE, et al. Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis. FASEB J. 2007;21(8):1844-1856
17. Raffin-Sanson ML, de Keyzer Y, Bertagna X. Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions. Eur J Endocrinol. 2003;149(2):79-90
18. Semple PL, Jane JA, Lopes MB, Laws ER. Pituitary apoplexy: correlation between magnetic resonance imaging and histopathological results. J Neurosurg. 2008;108 (5):909-915
19. Vieira JO Jr, Cukiert A, Liberman B. Magnetic resonance imaging of cavernous sinus invasion by pituitary adenoma diagnostic criteria and surgical findings. Arq Neuropsiquiatr. 2004;62(2B):437-443
20. Cottier JP, Destrieux C, Brunereau L, et al. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology. 2000;215(2):463-469
21. Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010;1(2):80-92.